Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

83.38 -0.73 (-0.87%)
Streaming Delayed Price Updated: 2:28 PM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
2 Cash-Producing Stocks to Research Further and 1 Facing Challenges
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
Ani (ANIP) Q1 2026 Earnings Call Transcript ↗
Ani (ANIP) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
2 Growth Stocks with Explosive Upside and 1 We Avoid
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil... 
Via StockStory
ANI Pharmaceuticals (NASDAQ:ANIP) Crushes Q1 Estimates, Raises Full-Year Guidance ↗
Via Chartmill
ANI Pharmaceuticals Inc (NASDAQ:ANIP) Surges 12% After Q4 Earnings Beat ↗
Via Chartmill
News headline image
Q1 Earnings Outperformers: ANI Pharmaceuticals (NASDAQ:ANIP) And The Rest Of The Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
2 Profitable Stocks with Competitive Advantages and 1 Facing Headwinds
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ... 
Via StockStory
News headline image
Global Alpha Dumps 229,000 Ani Pharmaceuticals (ANIP) Shares Worth $17.9 Million ↗
ANI Pharmaceuticals develops and manufactures branded and generic drugs for diverse North American healthcare markets. 
Via The Motley Fool
News headline image
ANI Pharmaceuticals Q1 Earnings Call Highlights ↗
ANI Pharmaceuticals (NASDAQ:ANIP) reported first-quarter 2026 results that management said show continued progress in its effort to “accelerat[e] our transformation into a leading rare disease... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
ANI Pharmaceuticals (NASDAQ:ANIP) Delivers Impressive Q1 CY2026, Stock Soars
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q1 CY2026, with sales up 20.5% year on year to $... 
Via StockStory
News headline image
ANI Pharmaceuticals (ANIP) Q1 Earnings: What To Expect
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) will be reporting earnings this Friday before market open. Here’s what you need to know. A... 
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q4 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) In The Context Of Other Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Winners And Losers Of Q4: Elanco (NYSE:ELAN) Vs The Rest Of The Pharmaceuticals Stocks
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Elanco (NYSE:ELAN) and its peers. The pharmaceuti... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Cash-Producing Stock with Promising Prospects and 2 Facing Challenges
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient... 
Via StockStory
Topics Economy
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Turn Down
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
Artivion, ANI Pharmaceuticals, and Privia Health Shares Are Soaring, What You Need To Know
What Happened? A number of stocks jumped in the afternoon session after the government announced a surprise increase in payment rates for Medicare Advantage ... 
Via StockStory
News headline image
3 Russell 2000 Stocks We Steer Clear Of
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
ANI Pharma Insider Sells 4,772 Shares as Revenue Hits $883 Million in 2025 ↗
Specializing in branded and generic pharmaceuticals, this sector player reported a notable insider sale amid a stable transaction pattern. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Reasons ANIP is Risky and 1 Stock to Buy Instead
What a brutal six months it’s been for ANI Pharmaceuticals. The stock has dropped 22.2% and now trades at $73.90, rattling many shareholders. This may have i... 
Via StockStory
Topics Supply Chain
News headline image
2 of Wall Street’s Favorite Stocks Worth Your Attention and 1 We Question
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
Pharmaceuticals Stocks Q4 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Profitable Stocks That Concern Us
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi... 
Via StockStory
News headline image
Q4 Earnings Roundup: Amneal (NASDAQ:AMRX) And The Rest Of The Generic Pharmaceuticals Segment
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amneal (NASDAQ:AMRX) and its peers. The g... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Generic Pharmaceuticals Q4 Earnings: ANI Pharmaceuticals (NASDAQ:ANIP) Simply the Best
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the generic pharmaceuticals industry, including ANI Pharmaceutica... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Clover Health, Alignment Healthcare, Solventum, ANI Pharmaceuticals, and Guardant Health Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after a surprisingly hot wholesale inflation report fueled investor concerns about persistent price pressures. 
Via StockStory
Topics Economy Stocks
News headline image
ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript ↗
ANI Pharma (ANIP) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ANI Pharmaceuticals (NASDAQ:ANIP) Beats Expectations in Strong Q4 CY2025, Stock Jumps 12.4%
Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ:ANIP) announced better-than-expected revenue in Q4 CY2025, with sales up 29.6% year on year to $247.1 million. The company’s full-year... 
Via StockStory
News headline image
1 Safe-and-Steady Stock Worth Your Attention and 2 That Underwhelm
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
News headline image
3 Small-Cap Stocks That Fall Short
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
1 Cash-Producing Stock on Our Buy List and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
Topics Supply Chain
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.